Cargando…

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

Various immune signatures predictive of resistance to immune checkpoint inhibitors (ICI) have been described in multiple solid cancers, but still under-investigated in gynecological (GYN) cancer. For 49 GYN cancer patients included in our study, without transcriptome signature, immune-related toxici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Ying, Soliman, Ahmed, Joehlin-Price, Amy, Rose, Peter G., Vlad, Anda, Edwards, Robert P., Mahdi, Haider
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683510/ https://www.ncbi.nlm.nih.gov/pubmed/34921236 http://dx.doi.org/10.1038/s41698-021-00242-8

Ejemplares similares

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()
por: Kuznicki, Michelle L., et al.
Publicado: (2020)

Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities
por: Mahdi, Haider, et al.
Publicado: (2021)

Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities
por: Azarianpour, Sepideh, et al.
Publicado: (2022)

Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study
por: Abbas, Ata, et al.
Publicado: (2021)

TGFβ: Signaling Blockade for Cancer Immunotherapy
por: Chen, Szu-Ying, et al.
Publicado: (2022)

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
por: Ravi, Rajani, et al.
Publicado: (2018)

The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF-β as a Companion Target for Checkpoint Blockade Immunotherapy
por: Bartlett, Bjarne, et al.
Publicado: (2021)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma
por: Yu, Qian, et al.
Publicado: (2022)

TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
por: Dahmani, Amina, et al.
Publicado: (2018)

NK Cell Metabolism and TGFβ – Implications for Immunotherapy
por: Slattery, Karen, et al.
Publicado: (2019)

Targeting immunosuppression by TGF-β1 for cancer immunotherapy
por: de Streel, Grégoire, et al.
Publicado: (2021)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
por: Pavicic, Paul G., et al.
Publicado: (2023)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
por: Maurer, Kathryn, et al.
Publicado: (2017)

A narrative review of the relationship between TGF-β signaling and gynecological malignant tumor
por: Luo, Fangyuan, et al.
Publicado: (2021)

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
por: Bai, Xianguang, et al.
Publicado: (2019)

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy
por: Lu, Mei, et al.
Publicado: (2020)

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
por: Tschernia, Nicholas P., et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Update on immune checkpoint inhibitors in gynecological cancers
por: Heong, Valerie, et al.
Publicado: (2017)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
por: Capalbo, Carlo, et al.
Publicado: (2019)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Emerging Targets of Immunotherapy in Gynecologic Cancer
por: Cheng, Hongyan, et al.
Publicado: (2020)

New Insights into Immunotherapy for Gynecological Cancer
por: Kobori, Takuro
Publicado: (2022)

Evaluation of immunotherapy efficacy in gynecologic cancer
por: Jiang, Genyi, et al.
Publicado: (2023)

Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
por: Benjamin, David J., et al.
Publicado: (2021)

Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases()
por: Moulton, Laura J., et al.
Publicado: (2017)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
por: Drakes, Maureen L., et al.
Publicado: (2020)

Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
por: Pirš, Boštjan, et al.
Publicado: (2022)

Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy
por: Löffek, Stefanie
Publicado: (2018)

MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location
por: Tirodkar, Tejas S., et al.
Publicado: (2014)

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma
por: Wu, Xin, et al.
Publicado: (2023)

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
por: Anko, Mayuka, et al.
Publicado: (2021)

Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2023)

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma
por: Li, Shaowen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ppid1nd58o3mcbsklijafpbs5p